{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:32:28Z","timestamp":1777635148241,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"am","delay-in-days":433,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01-HL085561"],"award-info":[{"award-number":["R01-HL085561"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["R01-HL097047"],"award-info":[{"award-number":["R01-HL097047"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01HX002422"],"award-info":[{"award-number":["I01HX002422"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007217","name":"Health Services Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007217","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.pcad.2022.06.009","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T20:41:28Z","timestamp":1656448888000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension"],"prefix":"10.1016","volume":"73","author":[{"given":"Phillip H.","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Tsimploulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkatesh K.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherinne","family":"Arundel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Faselis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakash","family":"Deedwania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farooq H.","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajal K.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Allman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2022.06.009_bb0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/HYPERTENSIONAHA.108.119792","article-title":"Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study","volume":"53","author":"Ekundayo","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.pcad.2022.06.009_bb0010","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/jama.1997.03550030052033","article-title":"Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group","volume":"278","author":"Kostis","year":"1997","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2022.06.009_bb0015","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1016\/j.jacc.2019.04.022","article-title":"Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction","volume":"73","author":"Arundel","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0020","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0025","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1016\/j.amjmed.2020.08.030","article-title":"Systolic blood pressure and outcomes in older patients with HFpEF and hypertension","volume":"134","author":"Faselis","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2022.06.009_bb0030","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2022.06.009_bb0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.amjmed.2021.11.012","article-title":"Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with reduced ejection fraction","volume":"135","author":"Lam","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2022.06.009_bb0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2004.03.004","article-title":"Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design","volume":"148","author":"Fonarow","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2022.06.009_bb0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijcard.2011.10.089","article-title":"Design and rationale of studies of neurohormonal blockade and outcomes in diastolic heart failure using OPTIMIZE-HF registry linked to medicare data","volume":"166","author":"Zhang","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0050","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0055","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika."},{"key":"10.1016\/j.pcad.2022.06.009_bb0065","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity score to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0070","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjmed.2020.02.040","article-title":"Digoxin initiation and outcomes in patients with heart failure with preserved ejection fraction","volume":"133","author":"Lam","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2022.06.009_bb0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.amjmed.2019.06.040","article-title":"Prior heart failure hospitalization and outcomes in patients with heart failure with preserved and reduced ejection fraction","volume":"133","author":"Malik","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2022.06.009_bb0080","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.amjmed.2020.05.030","article-title":"Digoxin initiation and outcomes in patients with heart failure (HFrEF and HFpEF) and atrial fibrillation","volume":"133","author":"Singh","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2022.06.009_bb0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.amjmed.2020.11.019","article-title":"Loop diuretic prescription and long-term outcomes in heart failure: association modification by congestion","volume":"134","author":"Faselis","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.pcad.2022.06.009_bb0090","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/art.41803","article-title":"Cardiovascular safety of hydroxychloroquine in US veterans with rheumatoid arthritis","volume":"73","author":"Faselis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0095","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2003.11.039","article-title":"Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure","volume":"43","author":"Kalantar-Zadeh","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/CIRCHEARTFAILURE.108.825059","article-title":"Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors","volume":"2","author":"Guder","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2022.06.009_bb0105","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/hrt.2007.134973","article-title":"Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure","volume":"95","author":"Raphael","year":"2009","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2022.06.009_bb0110","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/ejhf.818","article-title":"Observations on the blood pressure paradox in heart failure","volume":"19","author":"Ventura","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2022.06.009_bb0115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.06.009_bb0120","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2022.06.009_bb0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacc.2020.06.022","article-title":"Loop diuretic prescription and 30-day outcomes in older patients with heart failure","volume":"76","author":"Faselis","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"40","key":"10.1016\/j.pcad.2022.06.009_bb0130","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehz395","article-title":"Digoxin-mortality: randomized vs. observational comparison in the DIG trial","volume":"40","author":"Aguirre Davila","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.06.009_bb0135","article-title":"The prevalent-user bias in observational studies and the importance of new-user design","author":"Ahmed","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2022.06.009_bb0140","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2020.02.009","article-title":"Systolic blood pressure in heart failure with preserved ejection fraction treated with Sacubitril\/valsartan","volume":"75","author":"Selvaraj","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2022.06.009_bb0145","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/ejhf.1060","article-title":"Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial","volume":"20","author":"Selvaraj","year":"2018","journal-title":"Eur J Heart Fail"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062022000706?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062022000706?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T05:21:53Z","timestamp":1777440113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062022000706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":29,"alternative-id":["S0033062022000706"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2022.06.009","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation of anti-hypertensive drugs and outcomes in patients with heart failure with preserved ejection fraction and persistent hypertension","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2022.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}